<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>14. CLINICAL STUDIES<BR><BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.1 Healing of Erosive or Ulcerative GERD<BR><BR>                     <BR>                        In a U.S., multicenter, randomized, double-blind, placebo-controlled study, 103 patients were treated for up to eight weeks with placebo, 10 mg, 20 mg or 40 mg ACIPHEX QD. For this and all studies of GERD healing, only patients with GERD symptoms and at least grade 2 esophagitis (modified Hetzel-Dent grading scale) were eligible for entry. Endoscopic healing was defined as grade 0 or 1. Each rabeprazole dose was significantly superior to placebo in producing endoscopic healing after four and eight weeks of treatment. The percentage of patients demonstrating endoscopic healing was as follows:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>TABLE 6 HEALING OF EROSIVE OR ULCERATIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) PERCENTAGE OF PATIENTS HEALED<BR></caption><BR>                           <col width="16%" align="center"/><BR>                           <col width="22%" align="center"/><BR>                           <col width="22%" align="center"/><BR>                           <col width="22%" align="center"/><BR>                           <col width="18%" align="center"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="5" align="left"><BR>*(p&lt;0.001 versus placebo)<BR></td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Week<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>10 mg<br/>ACIPHEX QD<br/>N=27<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>20 mg<br/>ACIPHEX QD<br/>N=25<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>40 mg<br/>ACIPHEX QD<br/>N=26<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Placebo<br/>N=25<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>4<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>63%*<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>56%*<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>54%*<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>0%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>8<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>93%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>84%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>85%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>12%<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>In addition, there was a statistically significant difference in favor of the ACIPHEX 10 mg, 20 mg, and 40 mg doses compared to placebo at Weeks 4 and 8 regarding complete resolution of GERD heartburn frequency (p≤0.026). All ACIPHEX groups reported significantly greater rates of complete resolution of GERD daytime heartburn severity compared to placebo at Weeks 4 and 8 (p≤0.036). Mean reductions from baseline in daily antacid dose were statistically significant for all ACIPHEX groups when compared to placebo at both Weeks 4 and 8 (p≤0.007).<BR>                        In a North American multicenter, randomized, double-blind, active-controlled study of 336 patients, ACIPHEX was statistically superior to ranitidine with respect to the percentage of patients healed at endoscopy after four and eight weeks of treatment (see table below):<BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>TABLE 7 HEALING OF EROSIVE OR ULCERATIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) PERCENTAGE OF PATIENTS HEALED<BR></caption><BR>                           <col width="20%" align="center"/><BR>                           <col width="40%" align="center"/><BR>                           <col width="40%" align="center"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="3" align="left"><BR>*(p&lt;0.001 versus ranitidine)<BR></td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr valign="bottom"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Week<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX 20 mg QD<br/>N=167<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Ranitidine 150 mg QID<br/>N=169<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>4<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>59%*<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>36%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>8<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>87%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>66%<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>ACIPHEX 20 mg once daily was significantly more effective than ranitidine 150 mg QID in the percentage of patients with complete resolution of heartburn at Weeks 4 and 8 (p<0.001). ACIPHEX 20 mg once daily was also more effective in complete resolution of daytime heartburn (p≤0.025), and nighttime heartburn (p≤0.012) at both Weeks 4 and 8, with significant differences by the end of the first week of the study.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.2 Long-term Maintenance of Healing of Erosive or Ulcerative GERD<BR><BR>                     <BR>                        The long-term maintenance of healing in patients with erosive or ulcerative GERD previously healed with gastric antisecretory therapy was assessed in two U.S., multicenter, randomized, double-blind, placebo-controlled studies of identical design of 52 weeks duration. The two studies randomized 209 and 285 patients, respectively, to receive either 10 mg or 20 mg of ACIPHEX QD or placebo. As demonstrated in the tables below, ACIPHEX was significantly superior to placebo in both studies with respect to the maintenance of healing of GERD and the proportions of patients remaining free of heartburn symptoms at 52 weeks:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>TABLE 8 PERCENT OF PATIENTS IN ENDOSCOPIC REMISSION<BR></caption><BR>                           <col width="25%" align="left"/><BR>                           <col width="25%" align="center"/><BR>                           <col width="25%" align="center"/><BR>                           <col width="25%" align="center"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="4" align="left"><BR>*(p&lt;0.001 versus placebo)<BR></td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX 10 mg<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX 20 mg<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Placebo<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Study 1<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=66<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=67<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=70<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 4<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>83%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>96%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>44%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 13<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>79%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>93%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>39%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 26<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>77%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>93%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>31%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 39<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>76%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>91%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>30%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 52<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>73%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>90%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>29%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Study 2<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=93<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=93<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=99<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 4<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>89%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>94%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>40%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 13<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>86%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>91%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>33%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 26<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>85%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>89%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>30%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 39<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>84%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>88%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>29%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 52<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>77%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>86%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>29%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>COMBINED STUDIES<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=159<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=160<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>N=169<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 4<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>87%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>94%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>42%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 13<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>83%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>92%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>36%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 26<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>82%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>91%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>31%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 39<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>81%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>89%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>30%<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Week 52<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>75%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>87%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>29%<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>TABLE 9 PERCENT OF PATIENTS WITHOUT RELAPSE IN HEARTBURN FREQUENCY AND DAYTIME AND NIGHTTIME HEARTBURN SEVERITY AT WEEK 52<BR></caption><BR>                           <col width="34%" align="left"/><BR>                           <col width="22%" align="center"/><BR>                           <col width="22%" align="center"/><BR>                           <col width="22%" align="center"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="4" align="left"><BR>* p&#8804;0.001 versus placebo<br/><BR>                                    <sup>&#8224;</sup> 0.001&lt;p&lt;0.05 versus placebo<BR></td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr valign="bottom"><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX<br/>10 mg<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX<br/>20 mg<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Placebo<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Heartburn Frequency<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Study 1<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>46/55 (84%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>48/52 (92%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>17/45 (38%)<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Study 2<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>50/72 (69%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>57/72 (79%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>22/79 (28%)<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Daytime Heartburn Severity<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Study 1<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>61/64 (95%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>60/62 (97%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>42/61 (69%)<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Study 2<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>73/84 (87%)<sup>&#8224;</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>82/87 (94%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>67/90 (74%)<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Nighttime Heartburn Severity<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Study 1<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>57/61 (93%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>60/61 (98%)*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>37/56 (66%)<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>&#160;&#160;&#160;Study 2<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>67/80 (84%)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>79/87 (91%)<sup>&#8224;</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>64/87 (74%)<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.3 Treatment of Symptomatic GERD<BR><BR>                     <BR>                        Two U.S., multicenter, double-blind, placebo controlled studies were conducted in 316 patients with daytime and nighttime heartburn. Patients reported 5 or more periods of moderate to very severe heartburn during the placebo treatment phase the week prior to randomization. Patients were confirmed by endoscopy to have no esophageal erosions.<BR>                        The percentage of heartburn free daytime and/or nighttime periods was greater with ACIPHEX 20 mg compared to placebo over the 4 weeks of study in Study RAB-USA-2 (47% vs. 23%) and Study RAB-USA-3 (52% vs. 28%). The mean decreases from baseline in average daytime and nighttime heartburn scores were significantly greater for ACIPHEX 20 mg as compared to placebo at week 4. Graphical displays depicting the daily mean daytime and nighttime scores are provided in Figures 2 to 5.<BR>                        FIGURE 2: MEAN DAYTIME HEARTBURN SCORES RAB-USA-2<BR>                        <BR>                        FIGURE 3: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-2<BR>                        <BR>                        FIGURE 4: MEAN DAYTIME HEARTBURN SCORES RAB-USA-3<BR>                        <BR>                        FIGURE 5: MEAN NIGHTTIME HEARTBURN SCORES RAB-USA-3<BR>                        <BR>                        In addition, the combined analysis of these two studies showed ACIPHEX 20 mg significantly improved other GERD-associated symptoms (regurgitation, belching and early satiety) by week 4 compared with placebo (all p values < 0.005).<BR>                        ACIPHEX 20 mg also significantly reduced daily antacid consumption versus placebo over 4 weeks (p<0.001).<BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>aciphex-02<BR><BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>aciphex-03<BR><BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>aciphex-04<BR><BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>aciphex-05<BR><BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.4 Healing of Duodenal Ulcers<BR><BR>                     <BR>                        In a U.S., randomized, double-blind, multicenter study assessing the effectiveness of 20 mg and 40 mg of ACIPHEX QD versus placebo for healing endoscopically defined duodenal ulcers, 100 patients were treated for up to four weeks. ACIPHEX was significantly superior to placebo in producing healing of duodenal ulcers. The percentages of patients with endoscopic healing are presented below:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>TABLE 10 HEALING OF DUODENAL ULCERS PERCENTAGE OF PATIENTS HEALED<BR></caption><BR>                           <col width="12%" align="center"/><BR>                           <col width="32%" align="center"/><BR>                           <col width="32%" align="center"/><BR>                           <col width="24%" align="center"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="4" align="left"><BR>* p&#8804;0.001 versus placebo<BR></td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule" valign="middle"><BR>Week<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX 20 mg QD<br/>N=34<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX 40 mg QD<br/>N=33<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Placebo<br/>N=33<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>2<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>44%<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>42%<BR></td><BR>                                 <td styleCode="Lrule Rrule"><BR>21%<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>4<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>79%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>91%*<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>39%<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>At Weeks 2 and 4, significantly more patients in the ACIPHEX 20 and 40 mg groups reported complete resolution of ulcer pain frequency (p≤0.018), daytime pain severity (p≤0.023), and nighttime pain severity (p≤0.035) compared with placebo patients. The only exception was the ACIPHEX 40 mg group versus placebo at Week 2 for duodenal ulcer pain frequency (p=0.094). Significant differences in resolution of daytime and nighttime pain were noted in both ACIPHEX groups relative to placebo by the end of the first week of the study. Significant reductions in daily antacid use were also noted in both ACIPHEX groups compared to placebo at Weeks 2 and 4 (p<0.001).<BR>                        An international randomized, double-blind, active-controlled trial was conducted in 205 patients comparing 20 mg ACIPHEX QD with 20 mg omeprazole QD. The study was designed to provide at least 80% power to exclude a difference of at least 10% between ACIPHEX and omeprazole, assuming four-week healing response rates of 93% for both groups. In patients with endoscopically defined duodenal ulcers treated for up to four weeks, ACIPHEX was comparable to omeprazole in producing healing of duodenal ulcers. The percentages of patients with endoscopic healing at two and four weeks are presented below:<BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>TABLE 11 HEALING OF DUODENAL ULCERS PERCENTAGE OF PATIENTS HEALED<BR></caption><BR>                           <col width="12%" align="center"/><BR>                           <col width="26%" align="center"/><BR>                           <col width="26%" align="center"/><BR>                           <col width="36%" align="center"/><BR>                           <tbody><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule" valign="middle"><BR>Week<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>ACIPHEX<br/>20 mg QD<br/>N=102<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Omeprazole<br/>20 mg QD<br/>N=103<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>95% Confidence Interval for the Treatment Difference (ACIPHEX - Omeprazole)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>2<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>69%<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>61%<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(-6%, 22%)<BR></td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>4<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>98%<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>93%<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>(-3%, 15%)<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>ACIPHEX and omeprazole were comparable in providing complete resolution of symptoms.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.5 Helicobacter pylori Eradication in Patients with Peptic Ulcer Disease or Symptomatic Non-Ulcer Disease<BR><BR>                     <BR>                        The U.S. multicenter study was a double-blind, parallel-group comparison of rabeprazole, amoxicillin, and clarithromycin for 3, 7, or 10 days vs. omeprazole, amoxicillin and clarithromycin for 10 days. Therapy consisted of rabeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (RAC) or omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (OAC). Patients with H. pylori infection were stratified in a 1:1 ratio for those with peptic ulcer disease (active or a history of ulcer in the past five years) [PUD] and those who were symptomatic but without peptic ulcer disease [NPUD], as determined by upper gastrointestinal endoscopy. The overall H. pylori eradication rates, defined as negative 13C-UBT for H. pylori ≥ 6 weeks from the end of the treatment are shown in the following table. The eradication rates in the 7-day and 10-day RAC regimens were found to be similar to 10-day OAC regimen using either the Intent-to-Treat (ITT) or Per-Protocol (PP) populations. Eradication rates in the RAC 3-day regimen were inferior to the other regimens.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%"><BR>                           <caption><BR>TABLE 12 HELICOBACTER PYLORI ERADICATION AT &#8805; 6 WEEKS AFTER THE END OF TREATMENT<BR></caption><BR>                           <col width="24%" align="center"/><BR>                           <col width="20%" align="center"/><BR>                           <col width="20%" align="center"/><BR>                           <col width="36%" align="center"/><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="4" align="left"><BR>                                    <sup>a</sup> Patients were included in the analysis if they had <content styleCode="italics">H. pylori</content> infection documented at baseline, defined as a positive <sup>13</sup>C-UBT plus rapid urease test or culture and were not protocol violators. Patients who dropped out of the study due to an adverse event related to the study drug were included in the evaluable analysis as failures of therapy.<br/><BR>                                    <sup>b</sup> Patients were included in the analysis if they had documented <content styleCode="italics">H. pylori</content> infection at baseline as defined above and took at least one dose of study medication. All dropouts were included as failures of therapy.<br/>* The 95% confidence intervals for the difference in eradication rates for 7-day RAC minus 10-day RAC are (- 9.3, 6.0) in the PP population and (-9.0, 7.5) in the ITT population.<BR></td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"/><BR>                                 <td colspan="2" styleCode="Botrule Lrule Rrule"><BR>Treatment Group<br/>Percent (%) of Patients Cured<br/>(Number of Patients)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Difference<br/>(RAC - OAC)<br/>[95% Confidence Interval]<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule"/><BR>                                 <td styleCode="Botrule"><BR>                                    <content styleCode="bold">7-day RAC*</content><BR>                                 </td><BR>                                 <td styleCode="Botrule"><BR>                                    <content styleCode="bold">10-day OAC</content><BR>                                 </td><BR>                                 <td styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Per Protocol<sup>a</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>84.3%<br/>(N=166)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>81.6%<br/>(N=179)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>2.8<br/>[- 5.2, 10.7]<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Intent-to-Treat<sup>b</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>77.3%<br/>(N=194)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>73.3%<br/>(N=206)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>4.0<br/>[- 4.4, 12.5]<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule"/><BR>                                 <td styleCode="Botrule"><BR>                                    <content styleCode="bold">10-day RAC*</content><BR>                                 </td><BR>                                 <td styleCode="Botrule"><BR>                                    <content styleCode="bold">10-day OAC</content><BR>                                 </td><BR>                                 <td styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Per Protocol<sup>a</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>86.0%<br/>(N=171)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>81.6%<br/>(N=179)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>4.4<br/>[- 3.3, 12.1]<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Intent-to-Treat<sup>b</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>78.1%<br/>(N=196)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>73.3%<br/>(N=206)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>4.8<br/>[- 3.6, 13.2]<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule"/><BR>                                 <td styleCode="Botrule"><BR>                                    <content styleCode="bold">3-day RAC</content><BR>                                 </td><BR>                                 <td styleCode="Botrule"><BR>                                    <content styleCode="bold">10-day OAC</content><BR>                                 </td><BR>                                 <td styleCode="Botrule Rrule"/><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Per Protocol<sup>a</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>29.9%<br/>(N=167)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>81.6%<br/>(N=179)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>- 51.6<br/>[- 60.6, - 42.6]<BR></td><BR>                              </tr><BR>                              <tr valign="top"><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>Intent-to-Treat<sup>b</sup><BR>                                 </td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>27.3%<br/>(N=187)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>73.3%<br/>(N=206)<BR></td><BR>                                 <td styleCode="Botrule Lrule Rrule"><BR>- 46.0<br/>[- 54.8, - 37.2]<BR></td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>14.6 Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome<BR><BR>                     <BR>                        Twelve patients with idiopathic gastric hypersecretion or Zollinger-Ellison syndrome have been treated successfully with ACIPHEX at doses from 20 to 120 mg for up to 12 months. ACIPHEX produced satisfactory inhibition of gastric acid secretion in all patients and complete resolution of signs and symptoms of acid-peptic disease where present. ACIPHEX also prevented recurrence of gastric hypersecretion and manifestations of acid-peptic disease in all patients. The high doses of ACIPHEX used to treat this small cohort of patients with gastric hypersecretion were well tolerated.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>